15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering LeMaitre Vascular Inc, 3 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $94.00 to $127.00, so the covering firms are broadly aligned. The average target of $114.50 sits 42% above the current $80.72. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.78 next quarter toward $3.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy375%
Hold125%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to LeMaitre Vascular Inc.
As of Sep, 3 of 4 firms rate LMAT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LMAT EPS & revenue forecast
EPS · NEXT QUARTER
$0.78
Range $0.77 – $0.79 · 8 analysts · +14% YoY
Next period, 8 analysts expect LeMaitre Vascular Inc to earn $0.78 a share (range $0.77 – $0.79), versus $0.68 a year earlier. Full-year consensus is $2.88, growing to $3.18 the year after.
REVENUE · NEXT QUARTER
$72.2M
Range $72.0M – $72.6M · 8 analysts · +12% YoY
Revenue is expected to reach $72.2M (range $72.0M – $72.6M), +12.1% year-over-year. Full-year consensus is $276.5M, rising to $302.9M next year.
Top analysts covering LeMaitre Vascular Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LMAT.
#1
Ross Osborn
Cantor Fitzgerald · Rank #166
Hold
$95.00+17.7% to target
Overall win rate
33%
+ Follow
#2
Michael Petusky
Barrington Research · Rank #373
Buy
$120.00+48.7% to target
Overall win rate
31%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #394
Buy
$135.00+67.2% to target
Overall win rate
26%
+ Follow
#4
NT
Nathan Treybeck
Wells Fargo
Hold
$94.00+16.5% to target
Coverage
—
+ Follow
#5
KB
Kyle Bauser
Roth Capital
Buy
$117.00+44.9% to target
Coverage
—
+ Follow
LMAT stock forecast FAQ
What is LMAT's average 12-month price target?+
The 4 analysts with a live target average $114.50 for LeMaitre Vascular Inc over the next 12 months, ranging from a $127.00 high to a $94.00 low.
Is LMAT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LMAT?+
The Street-high target is $127.00 (Citizens), and the Street-low is $94.00 (Wells Fargo). The average of all 4 active targets is $114.50.
How many Wall Street analysts cover LMAT?+
4 analysts have an active rating on LeMaitre Vascular Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering LMAT?+
Among analysts who currently cover LMAT, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #166). Their current call is Hold with a $95.00 target.
What is LeMaitre Vascular Inc's projected EPS for next quarter?+
The consensus estimate is $0.78 per share (range $0.77 – $0.79) across 8 analysts. Full-year EPS is projected at $2.88, rising to $3.18 the following year.
How much revenue is LeMaitre Vascular Inc expected to report next quarter?+
Consensus revenue is $72.2M (range $72.0M – $72.6M). Full-year revenue is projected at $276.5M, growing to $302.9M next year.
Have analysts been upgrading or downgrading LMAT lately?+
As of Sep, 3 of 4 firms rate LMAT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LMAT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
